GlassScriptPhysician profile
David T Dulaney
NPI 1427443456
$116,712.32
in general payments reported to CMS, 2019-2025
16 companies · $85K in 2025
The $85K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $142 · 2021: $377 · 2022: $344 · 2023: $878 · 2024: $30K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $96K · Travel and Lodging: $15K · Food and Beverage: $4,184 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,589.16 |
| Travel and Lodging | $15,440.29 |
| Food and Beverage | $4,183.55 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33,928.74 | 2021-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $28,942.71 | 2023-2025 | Dupixent |
| Genzyme Corporation | $25,956.18 | 2023-2025 | |
| Lilly USA, LLC | $25,098.44 | 2022-2025 | Omvoh |
| Celgene Corporation | $858.91 | 2022-2024 | Zeposia |
| Abbvie INC. | $801.96 | 2019-2025 | Linzess, Skyrizi |
| Intercept Pharmaceuticals, INC. | $238.26 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.82 | 2019-2022 | |
| Medtronic, INC. | $148.48 | 2023 | Endoflip |
| Phathom Pharmaceuticals, INC. | $131.28 | 2024 | Voquezna |
| Olympus America INC. | $124.68 | 2021 | |
| La Jolla Pharmaceutical Company | $118.41 | 2019 | |
| Pfizer INC. | $80.81 | 2025 | |
| Alnylam Pharmaceuticals INC. | $43.56 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $31.98 | 2024 | Dupixent |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dulaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.